Lineage Cell Therapeutics : Leading clinical-stage cell therapy company with in-house manufacturing capabilities and clinically validated technology. Innovative programs based on one of the largest and most comprehensive patent estates in cell therapy. 3 clinical programs in markets with billion dollar opportunities: 1) OpRegen, an RPE transplant therapy in Phase 1/2a development for the treatment of dry-AMD. Positive clinical results reported in first 16 enrolled patients, study expected to complete enrollment in Q1 2020 with an innovative delivery device from Orbit Biomedical Ltd.; 2) OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries with Orphan and RMAT designations. Positive clinical results reported from ongoing Phase 1/2a study for treatment of acute SCI. Program focus in 2020 are manufacturing enhancements and meeting with FDA to prepare for the next study; 3) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 for NSCLC conducted by CRUK. Company is also evaluating partnership opportunities to commercialize Renevia, a proprietary 3-D scaffold designed to support adipose tissue transplant and retention and which received a CE Mark in September 2019 for use in adults for the treatment of facial lipoatrophy.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Disease Space
Ophthalmology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Lineage Cell Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Broadwood Capital, Inc. 22.72 34,005,379 26.86 13F 2020-03-31
Greenway Partners LP 4.43 6,635,973 5.24 Stakes 2019-12-31
The Vanguard Group, Inc. 3.67 5,490,014 4.34 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 3.58 5,361,191 4.24 13F 2020-03-31
Defender Capital LLC 2.95 4,416,590 3.49 13F 2020-03-31
BlackRock Fund Advisors 2.61 3,901,799 3.08 13F 2020-03-31
BlackRock Institutional Trust Co. NA 1.82 2,724,147 2.15 13F 2020-03-31
Prescott General Partners LLC 1.24 1,851,851 1.46 13F 2020-03-31
State Street Corp. 1.17 1,753,991 1.39 13F 2020-03-31
Geode Capital Management LLC 1.12 1,677,519 1.33 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.